Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...

Approvals last year included rare disease treatments, new oncology drugs, Eli Lilly’s Kisunla, and Mesoblast's Ryoncil.

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Rajiv Onat, India head, digital technology and engineering, Regeneron, acknowledged Telangana’s role in creating a ...

The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The risi ...

PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company pioneering a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis (ALS), is pleased to ...

I always find myself rooting not necessarily for the actor who gave the best performance — because, really, who can say which ...

The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...